Prophylactic octreotide administration does not prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: A meta-analysis of randomized controlled trials

Pancreas

Volumn 37, Issue 3, 2008, Pages 241-246

  Bai, Yu ^a   Gao, Jun ^a   Zou, Duo Wu ^a   Li, Zhao Shen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Meta analysis; Octreotide; Post ERCP pancreatitis

Indexed keywords

OCTREOTIDE; PLACEBO; PROTECTIVE AGENT;

ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; EMBASE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PANCREATITIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; EVIDENCE BASED MEDICINE; PREMEDICATION; TREATMENT FAILURE;

CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; EVIDENCE-BASED MEDICINE; HUMANS; OCTREOTIDE; PANCREATITIS; PREMEDICATION; PROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT FAILURE;

EID: 58149340155     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31816c90a1     Document Type: Article

References (32)

1. Tsujino T, Isayama H, Komatsu Y, et al. Risk factors for pancreatitis in patients with common bile duct stones managed by endoscopic papillary balloon dilation. Am J Gastroenterol. 2005;100(1):38-42.
2. Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol. 2001;96(2):417-423.
3. Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc. 1998;48:1-10.
4. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc. 2001;54(4):425-434.
5. Andriulli A, Leandro G, Niro G, et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc. 2000;51(1):1-7.
6. Andriulli A, Leandro G, Federici T, et al. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc. 2007;65(4):624-632.
7. Li ZS, Pan X, Zhang WJ, et al. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: a multicenter, placebo-controlled, randomized clinical trial. Am J Gastroenterol. 2007;102(1):46-51.
8. Thomopoulos KC, Pagoni NA, Vagenas KA, et al. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis. Gastrointest Endosc. 2006;64(5):726-731.
9. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408-412.
10. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352(9128):609-613.
11. Begg CB. Publication bias. In: Cooper H, Hedges LV, eds. The Handbook of Research Synthesis. New York, NY: Russell Sage Foundation; 1994:399-410.
12. Skordilis PG, Voumvouraki A, Vardas E, et al. Somatostatin can be efficient for the prevention of the post-ERCP pancreatitis? [Abstract] Endoscopy. 2005;37(1 suppl):A279.
13. Sternlieb JM, Aronchick CA, Retig JN, et al. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol. 1992;87(11): 1561-1566.
14. Binmoeller KF, Harris AG, Dumas R, et al. Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis? Gut. 1992;33(8):1129-1133.
15. Russo A, Virgilio C, Aprile G, et al. Influenza dell'octreotide sulla reazione pancreatica indotta da colangiopancreatografia retrograda. Giorn Ital End Dig. 1992;15:139-145.
16. Armonis A, Manolakopoulos S, Papadimitrious N, et al. The effect of long acting somatostatin analogue in the prevention of post-ERCP pancreatitis. Gut. 1994;35(suppl 4):A85.
17. Testoni PA, Lella F, Bagndo F, et al. Controlled trial of different dosages of octreotide in the prevention of hyperamylasemia induced by endoscopic papillosphincterotomy. Ital J Gastroenterol. 1994;26(9):431-436.
18. Arcidiacono R, Gambitta P, Rossi A, et al. The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. Endoscopy. 1994;26(9):715-718.
19. Testoni PA, Lella F, Bagnolo F, et al. Long-term prophylactic administration of octreotide reduces the rise in serum amylase after endoscopic procedures on Vater's papilla. Pancreas. 1996;13(1):61-65.
20. Ng KW, Jiang CF, Liang CT, et al. A prospective, randomized, controlled trial to evaluate the effect of prophylactic sandostatin on ERCP-induced hyperamylasemia and pancreatitis. Gastroenterol J Taiwan. 1997;14(2):192-197.
21. Arvanitidis D, Hatzipanayiotis J, Koutsounopoulos G, et al. The effect of octreotide on the prevention of acute pancreatitis and hyperamylasemia after diagnostic and therapeutic ERCP. Hepatogastroenterology. 1998;45(19):248-252.
22. Duvnjak M, Supanc V, Simicevic VN, et al. Use of octreotide-acetate in preventing pancreatitis-like changes following therapeutic endoscopic retrograde cholangiopancreatography. Acta Med Croatica. 1999;53(3): 115-118.
23. Badra G, Galad AS, Rowaish I, et al. Allopurinol vs octreotide in the prevention of post-ERCP pancreatitis in patient with billiary obstruction. A randomized controlled trial. Hepatology. 2000;32(4):163A.
24. Testoni PA, Bagnolo F, Andriulli A, et al. Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther. 2001;15(7): 965-972.
25. Manolakopoulos S, Avgerinos A, Vlachogiannakos J, et al. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. Gastrointest Endosc. 2002;55(4):470-475.
26. Andriulli A, Loperfido S, Napolitano G, et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol. 2007;102(8):1781-1788.
27. Cook DJ, Guyatt GH, Ryan G, et al. Should unpublished data be included in meta-analyses? Current convictions and controversies. JAMA. 1993; 269(21):2749-2753.
28. McAuley L, Pham B, Tugwell P, et al. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet. 2000;356(9237):1228-1231.
29. Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 1991;37(3):383-393.
30. Masci E, Mariani A, Curioni S, et al. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis. Endoscopy. 2003;35(10):830-834.
31. Testoni PA. Facts and fiction in the pharmacologic prevention of post-ERCP pancreatitis: a never-ending story. Gastrointest Endosc. 2006;64(5):732-734.
32. Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc. 2004;59(7):845-864.